SAN FRANCISCO — The combination of an immunotherapy and a vascular endothelial growth factor (VEGF) inhibitor resulted in a groundbreaking response rate in metastatic renal cell carcinoma (RCC), according to results of an ongoing phase 1b study. In a cohort of treatment-naive patients, 38 of 52 (73%) achieved an objective response, including 4 complete responses,...